VEGF-D promotes the metastatic spread of tumor cells via the lymphatics (original) (raw)

• Liotta, L.A. Cancer cell invasion and metastasis. Sci. Am. 266, 34–41 (1992).
  Article Google Scholar
• O'Reilly, M.S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the supression of metastases by a lewis lung carcinoma. Cell 79, 315–328 (1994).
  Article CAS Google Scholar
• O'Reilly, M.S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).
  Article CAS Google Scholar
• Millauer, B., Shawver, L.K., Plate, K.H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature 367, 576–579 (1994).
  Article CAS Google Scholar
• Millauer, B. et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56, 1615–1620 (1996).
  CAS PubMed Google Scholar
• Kim, K.J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844 (1993).
  Article CAS Google Scholar
• Saleh, M., Stacker, S.A. & Wilks, A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56, 393–401 (1996).
  CAS PubMed Google Scholar
• Achen, M.G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk-1) and VEGF receptor 3 (Flt-4). Proc. Natl. Acad. Sci. USA 95, 548–553 (1998).
  Article CAS Google Scholar
• Orlandini, M., Marconcini, L., Ferruzzi, R. & Oliviero, S. Identification of a C-_Fos_-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl. Acad. Sci. USA 93, 11675–11680 (1996).
  Article CAS Google Scholar
• Kaipainen, A. et al. Expression of the Fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 92, 3566–3570 (1995).
  Article CAS Google Scholar
• Taipale, J. et al. Vascular endothelial growth factor receptor-3. Curr. Top. Microbiol. Immunol. 237, 85–96 (1999).
  CAS PubMed Google Scholar
• Dukes, C.E. The classification of cancer of the rectum. J. Pathol. 35, 323–332 (1932).
  Article Google Scholar
• Fisher, B. et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52, 1551–1557 (1983).
  Article CAS Google Scholar
• Stacker, S.A. & Achen, M.G. The vascular endothelial growth factor family: signaling for vascular development. Growth Factors 17, 1–11 (1999).
  Article CAS Google Scholar
• Stacker, S.A. et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J. Biol. Chem. 274, 32127–32136 (1999).
  Article CAS Google Scholar
• Achen, M.G. et al. Monoclonal antibodies to vascular endothelial growth factor-D block interactions with both VEGF receptor-2 and VEGF receptor-3. Eur.J.Biochem. 267, 2505–2515 (2000).
  Article CAS Google Scholar
• Valtola, R. et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 154, 1381–1390 (1999).
  Article CAS Google Scholar
• Banerji, S. et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144, 789–801 (1999).
  Article CAS Google Scholar
• de Waal, R.M.W. et al. Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination. Am. J. Pathol. 150, 1951–1957 (1997).
  CAS PubMed PubMed Central Google Scholar
• Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209–5218 (1999).
  CAS PubMed Google Scholar
• Whiteside, T.L. & Herberman, R.B. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7, 704–710 (1995).
  Article CAS Google Scholar
• Vujanovic, N.L., Basse, P., Herberman, R.B. & Whiteside, T.L. Antitumor functions of natural killer cells and control of metastases. Methods 9, 394–408 (1996).
  Article CAS Google Scholar
• Babu, S., Porte, P., Klei, T.R., Shultz, L.D. & Rajan, T.V. Host NK cells are required for the growth of the human filarial parasite Brugia malayi in mice. J. Immunol. 161, 1428–1432 (1998).
  CAS PubMed Google Scholar
• Ansink, A.C. et al. Identification of sentinel lymph nodes in vulvar carcinoma patients with the aid of a Patent Blue V injection: a multicenter study. Cancer 86, 652–656 (1999).
  Article CAS Google Scholar
• Folkman, J. Anti-angiogenesis: new concepts of therapy of solid tumors. Ann. Surg. 175, 409–416 (1972).
  Article CAS Google Scholar
• Folkman, J. & Klagsburn, M. Angiogenic factors. Science 235, 442–447 (1987).
  Article CAS Google Scholar
• Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4–6 (1990).
  Article CAS Google Scholar
• Folkman, J. & D'Amore, P.A. Blood vessel formation:what is its molecular basis? Cell 87, 1153–1155 (1996).
  Article CAS Google Scholar
• Wood, J.M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178–2189 (2000).
  CAS Google Scholar
• Drevs, J. et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60, 4819–4824 (2000).
  CAS Google Scholar
• Lymboussaki, A., Achen, M.G., Stacker, S.A. & Alitalo, K. Growth factors regulating lymphatic vessels. Curr. Top. Microbiol. Immunol. 251, 75–82 (2000)
  CAS PubMed Google Scholar
• Leu, A.J., Berk, D.A., Lymboussaki, A., Alitalo, K. & Jain, R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60, 4324–4327 (2000).
  CAS PubMed Google Scholar
• Lymboussaki, A. et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am. J. Pathol. 153, 395–403 (1998).
  Article CAS Google Scholar
• Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, Is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 290–298 (1996).
  Article CAS Google Scholar
• Kubo, H. et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96, 546–553 (2000).
  CAS PubMed Google Scholar
• Salven, P. et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am. J. Pathol. 153, 103–108 (1998).
  Article CAS Google Scholar
• Achen, M.G. et al. Localisation of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis J. Pathol. (in the press).
• Plate, K.H., Breier, G., Millauer, B., Ullrich, A. & Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53, 5822–5827 (1993).
  CAS PubMed Google Scholar
• Niki, T. et al. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin. Cancer Res. 6, 2431–2439 (2000).
  CAS PubMed Google Scholar
• Mandriota, S.J. et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis. EMBOJ. in press (2001).
• Layton, J.E., Iaria, J. & Nicholson, S.E. Neutralising antibodies to the granulocyte colony-stimulating factor receptor recognise both the immunoglobulin-like domain and the cytokine receptor homologous domain. Growth Factors. 14, 117–130 (1997).
  Article CAS Google Scholar